Incyte announces validation by EMA of its MAA for pemigatinib in patients with cholangiocarcinoma
Incyte announced the validation of the Company’s Marketing Authorization Application (MAA) for pemigatinib for the treatment of adults with locally advanced or metastatic…
Read More...
Read More...
